Quick Summary

Echinacea purpurea is a widely used medicinal plant studied for its immunomodulatory, antiviral, and anti-inflammatory properties. It has been commonly used for the prevention and treatment of respiratory tract infections, particularly in children. Clinical evidence supports potential benefits in reducing symptom duration, incidence, and antibiotic use associated with upper respiratory tract infections. The herb is generally well tolerated with mild adverse effects reported. However, heterogeneity in preparations and dosing affects the consistency of findings.

What is it?

Echinacea purpurea, commonly known as purple coneflower, is a flowering plant native to North America. It has a long history of use as an herbal remedy, particularly for conditions related to immune support and respiratory health.

Traditional Uses

Traditionally, Echinacea has been used to support the immune system and to help prevent and treat colds, flu, and other upper respiratory tract infections. It has also been applied topically for wound healing and skin issues.

Active Compounds

Echinacea contains a variety of phytochemicals including alkamides, caffeic acid derivatives (such as cichoric acid), polysaccharides, and flavonoids. These compounds are believed to contribute to its immunomodulatory and anti-inflammatory effects.

Potential Benefits with Evidence Levels

  • Reduction in acute respiratory tract infection incidence and severity in children: Moderate to high certainty. Systematic reviews and meta-analyses of randomized clinical trials indicate a significant reduction in infection incidence, fever duration, symptom severity, and antibiotic use. However, results vary with formulation and standardization.
  • Reduction in treatment duration, incidence, and antibiotic use for upper respiratory tract infections (URTI) in children: Moderate quality. Meta-analysis of nine randomized controlled trials (RCTs) involving over 3,000 participants shows benefits including shorter treatment duration and reduced antibiotic use. Evidence for otitis media is less conclusive.
  • Potential antiviral activity against coronaviruses, including reduction in viral load: Preliminary clinical evidence from two RCTs suggests reduced incidence and viral loads of enveloped viruses, including some coronaviruses. The clinical relevance for SARS-CoV-2 remains to be established in larger trials.
  • Adjunctive use in managing respiratory tract infections to reduce antibiotic demand: Moderate evidence from a meta-analysis of 30 clinical trials involving over 5,600 subjects shows significant reductions in respiratory tract infection occurrences, recurrences, complications, and antibiotic prescriptions.
  • Immunomodulatory effects: Supported by preclinical and mechanistic studies; human evidence is inconsistent and limited due to variability in preparations and bioavailability.

Side Effects

Echinacea is generally well tolerated in adults and children. Reported adverse effects are mostly mild and include gastrointestinal discomfort and skin rash. Rare serious adverse events, potentially related to hypersensitivity reactions, have been reported but causality is unclear. Overall adverse event rates are comparable to placebo.

Drug Interactions

Herb-drug interactions have been noted in the literature for immunomodulatory herbs including Echinacea. However, clinically significant interactions are not well defined due to variability in herbal product composition. No strong clinical evidence confirms notable pharmacokinetic or pharmacodynamic interactions. Caution is advised when Echinacea is taken concomitantly with other medications.

Who Should Avoid It

Due to limited clinical data, specific contraindications are not well established. Caution is recommended for individuals with known allergies to plants in the Asteraceae family or those with immune disorders pending further safety studies. Use during pregnancy or breastfeeding is not currently recommended without medical supervision, as safety has not been sufficiently established.

Evidence Limitations

  • Heterogeneity of clinical trials with variable formulations, dosages, and preparations reduces consistency of findings.
  • Lack of large, high-quality, standardized clinical trials addressing long-term safety and efficacy.
  • Insufficient data on safety in special populations such as pregnant or breastfeeding women.
  • Variability in extract composition impacts reproducibility of immunomodulatory and antiviral effects.
  • Limited mechanistic understanding of clinical immunomodulatory pathways and antiviral mechanisms in humans.
  • Some reported publication biases and risk of bias in included studies.
  • Unclear causality and mechanisms underlying rare serious adverse events observed in pharmacovigilance reports.

References

Last Reviewed

June 2024

Informational Disclaimer

This page is for informational purposes only and does not constitute medical advice. Echinacea should not be used as a substitute for professional healthcare diagnosis, treatment, or advice. Consult a healthcare provider before starting any new herbal regimen, especially if you are pregnant, breastfeeding, have existing health conditions, or take other medications.